Stock IBIO IBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages iBio, Inc.

Equities

IBIO

US4510337086

Market Closed - Nyse
Other stock markets
 16:00:00 2024-05-03 EDT 		5-day change 1st Jan Change
1.99 USD -1.97% Intraday chart for iBio, Inc. +13.07% +45.26%
04-01 IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors CI
03-28 Top Premarket Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
Top Midday Gainers
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings
Top Premarket Gainers
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Top Midday Decliners
Top Premarket Decliners
MÄRKTE USA/Aktien gut behauptet - Zinsen weiter auf dem Weg nach unten
MÄRKTE USA/Dow & Co kommen ins Laufen - Zinsumfeld hilft
MÄRKTE USA/Wall Street vor Daten kaum bewegt
MÄRKTE USA/Wall Street vor Daten knapp im Minus gesehen
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
IBio Unit, Woodforest National Bank Amend Credit Agreement
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
IBio Names Martin Brenner Chief Executive; Felipe Duran Appointed as Finance Chief
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBIO Stock
  4. News iBio, Inc.
  5. Other languages